Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM1ZY6M)

Drug Name
227Th-labelled MSLN-TTC Drug Info
Synonyms BAY2287411
Indication
Disease Entry ICD 11 Status REF
Epithelioid mesothelioma 2F10 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM1ZY6M

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mesothelin (MSLN) TT4RXME MSLN_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Mesothelin (MSLN) DTT MSLN -0.515 2.233 -0.152 0
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Epithelioid mesothelioma
ICD Disease Classification 2F10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Mesothelin (MSLN) DTT MSLN 2.86E-20 3.98 6.12
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03507452) First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin. U.S. National Institutes of Health.
2 Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers. Clin Cancer Res. 2019 Aug 1;25(15):4723-4734.